Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
ATMARINOMED6
Tue, 20.08.2024       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech AG reports preliminary financial figures for the first half of 2024 Revenues of EUR 2.5 million generated in the first half of 2024 (H1 2023: EUR 5.2 million); cash and cash equivalents as of 30.06.2024 at EUR 0.9 million (31.12.2023: EUR 2.6 million) Court restructuring proceedings without self-administration opened on August 1 [ … ]
Technical analysis
To the publication
Wed, 14.08.2024       Marinomed Biotech AG
ATMARINOMED6

Korneuburg, Austria, 14. August 2024 – Marinomed Biotech AG (VSE:MARI) announces that on August 14, 2024, the Regional Court of Korneuburg opened restructuring proceedings without self-administration at the request of Marinomed Biotech AG. The Company expects trading of Marinomed shares to resume soon and a switch to the standard market continuous  [ … ]
Technical analysis
To the publication
Wed, 14.08.2024       Marinomed Biotech AG
ATMARINOMED6

 Marinomed Biotech AG aims for financial reorganization by restructuring proceedings without self-administration Application for opening of restructuring proceedings Funds necessary to secure liquidity could not be raised as planned This step is intended to ensure the Company's continued existence in the long term in agreement with its creditors [ … ]
Technical analysis
To the publication
Tue, 13.08.2024       Marinomed Biotech AG
ATMARINOMED6

Korneuburg, Austria, 13. August 2024 – Marinomed Biotech AG (VSE:MARI) announces to apply for the initiation of court restructuring proceedings. The aim is to carry out restructuring proceedings without self-administration. As a result of the inability to raise funds required at short notice to secure the Company’s liquidity, insolvency is imminent [ … ]
Technical analysis
To the publication
Fri, 14.06.2024       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech AG secures licensure with leading Consumer Health Care player for the distribution of Carragelose® products in Europe Marinomed signs an additional licensing agreement with an existing partner for the distribution and marketing of Carragelose® products in Europe and selected other countries Marinomed eligible to receive mileston [ … ]
Technical analysis
To the publication
Wed, 22.05.2024       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech AG announces results for the first quarter of 2024 Revenues for the first quarter 2024 declined to pre-pandemic levels of EUR 0.7 million driven by high customer stock levels and return of seasonality Q1 2024: New partnerships for Carragelose and Solv4U, agreement with financing partners for deferral of repayments and progress w [ … ]
Technical analysis
To the publication
Thu, 25.04.2024       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios Marinomed will apply the Marinosolv solubilization technology to improve target compounds with the goal of developing products with differentiated pharmacological profiles The project covers the proof-of-concept evaluation and future d [ … ]
Technical analysis
To the publication
Tue, 16.04.2024       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets Revenues for the 2023 financial year at EUR 9.2 million after pandemic-driven record years (2022: EUR 11.3 million) Important progress for Carragelose with new distribution partners and new products as well as Marinosolv  [ … ]
Technical analysis
To the publication
Thu, 11.04.2024       Marinomed Biotech AG
ATMARINOMED6

Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico Launch of new allergen-blocking nasal spray in Austria for the treatment of hay fever complements existing OTC product portfolio Partner M8 Pharmaceuticals launches Carragelose nasal spray for the treatment of viral respiratory infectio [ … ]
Technical analysis
To the publication
Thu, 28.03.2024       Marinomed Biotech AG
ATMARINOMED6

 Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months Agreement with the EIB provides for a deferral of all capital repayments for 18 months, while interest rates remain unchanged Real estate lenders also agreed to suspend repayments for 18 months Marinomed plans  [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Friday, 18.10.2024, Calendar Week 42, 292nd day of the year, 74 days remaining until EoY.